ElevateBio's Rapid Next-Generation Sequencing Services Are Designed To Support All Cell And Gene Therapy Modalities

Cell and gene therapy programs move quickly, and the sequencing data behind them has to keep pace. This rapid next-generation sequencing service was built to support every modality, pairing a broad menu of methods with the speed and customization developers need.

Available sequencing types include amplicon, whole genome, whole exome, RNA (including single-cell), complete plasmid, and methylation. Work runs on Illumina, Oxford Nanopore, and 10x Genomics instruments, so the platform can be matched to the scientific question rather than the other way around.

Three strengths define the offering. For data quality, partners get optimized processes and assay controls, high coverage of targets of interest, and a team with deep analytical and reporting expertise. For speed, amplicon workflows return sequencing results in under one week, advanced assay data arrives 2 to 4 weeks ahead of the industry standard, and automated pipelines streamline data processing and analysis. These turnaround claims apply to characterization work only. For flexibility, the team collaborates on assay and target design and optimization and offers consultation across every part of the workflow.

The service is also integrated with cGMP manufacturing and process development workflows at BaseCamp, keeping sequencing results closely tied to the decisions made on the manufacturing floor.

It comes from a technology-driven genetic medicines company whose scientists, builders, and operators work to accelerate access to cutting-edge technologies and end-to-end manufacturing capabilities.